# Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)

> **NCT00526474** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 26449 (actual)

## Conditions studied

- Atherosclerosis
- Ischemia
- Myocardial Infarction
- Cerebrovascular Accident
- Peripheral Arterial Disease

## Interventions

- **DRUG:** Vorapaxar
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00526474
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09-01
- **Primary completion:** 2011-12-01
- **Final completion:** 2011-12-01
- **Target enrollment:** 26449 (ACTUAL)
- **Last updated:** 2018-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00526474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00526474, "Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00526474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*